The prognosis of malignant gliomas remains poor, with median survival fewer than 20
months and a 5-year survival rate merely 5%. Their primary location in the central nervous …

Highlights•CVs have been characterized by positive safety and immunogenicity profiles but
low levels of clinical efficacy.•Novel CV strategies entail personalized formulations and …

Cancer Immunotherapy relies on harnessing a patient's immune system to fine-tune specific
anti-tumor responses and ultimately eradicate cancer. Among diverse therapeutic …

Oncolytic viruses (OVs) are emerging cancer therapeutics that offer a multifaceted
therapeutic platform for the benefits of replicating and lysing tumor cells, being engineered …

Head and neck cancer (HNC), which includes lip and oral cavity, larynx, nasopharynx,
oropharynx, and hypopharynx malignancies, is one of the most common cancers worldwide …

Recent cancer immunotherapy breakthroughs have fundamentally changed oncology and
revived the fading hope for a cancer cure. The immune checkpoint inhibitors (ICI) became …

Oncolytic viruses (OVs), viruses engineered to lyse tumor cells, work hand in hand with the
immune response. While for decades the field isolated lytic capability and viral spread to …

Oncolytic viruses (OVs) represent a highly promising treatment strategy for a wide range of
cancers, by mediating both the direct killing of tumor cells as well as mobilization of …

The therapeutic efficacy of oncolytic adenoviruses (OAs) relies on efficient viral transduction
and replication. However, the limited expression of coxsackie-adenovirus receptors in many …

Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the
available therapeutic options show a lack of efficacy, novel therapeutic strategies are …